Abstract: Disclosed herein are compositions comprising nanoparticle complexes comprising albumin-bound paclitaxel and an anti-VEGF antibody, wherein the ratio of albumin-paclitaxel to antibody is between 2:1 and 1:25. Additionally disclosed herein are methods using the compositions of the present invention, such as for treating a VEGF-expressing cancer in a mammal, for example, skin cancer.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
July 22, 2025
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-L1 are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists thereof.
Abstract: A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.
Abstract: The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1?) pathways and non-HIF-1? pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.
Type:
Grant
Filed:
December 10, 2021
Date of Patent:
April 29, 2025
Assignee:
Omniox, Inc.
Inventors:
Stephen P. L. Cary, Ana Krtolica, Natacha Le Moan, Jonathan A Winger, Kevin G. Leong
Abstract: The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.
Type:
Grant
Filed:
September 11, 2020
Date of Patent:
April 22, 2025
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Christina Claus, Claudia Ferrara Koller, Christian Klein, Johannes Sam, Pablo Umana
Abstract: This invention relates to a therapeutic composition comprising i) at least two immune checkpoint inhibitors, ii) at least one drug selected from a cytokine a cytotoxic or cytostatic chemotherapeutic drug, and combinations thereof, and iii) a cancer vaccine prepared from tumor or cancer cells, or derivatives thereof, that have been prepared through an ex vivo treatment that creates necrotic and/or necroptotic cancer cells while minimizing destruction of cancer antigens. This invention also relates to a method of treating a tumor or a cancer in a patient comprising administering to a patient in need thereof the therapeutic composition in an amount effective to treat the tumor or cancer.
Type:
Grant
Filed:
February 11, 2022
Date of Patent:
April 1, 2025
Assignee:
Rampart Health, L.L.C.
Inventors:
David Granger Bostwick, Brian Rafferty Bostwick, Peter John Littrup
Abstract: The disclosure relates to methods for treating cancers (e.g., cancers having a BRCA1 and/or BRCA2 mutation(s)) by administering to the subject an effective amount of a ubiquitin-specific protease 1 (USP1) inhibitor.
Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).
Type:
Grant
Filed:
October 30, 2019
Date of Patent:
March 4, 2025
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Lori Volles, Rajendra Pradhan, Douglas L. Sheridan, Marc Vallee, Xiang Gao
Abstract: The present disclosure is directed to antibodies binding previously undefined epitopes on influenza A virus hemagglutinin and methods for use thereof.
Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
Type:
Grant
Filed:
March 13, 2023
Date of Patent:
February 18, 2025
Assignee:
Sanofi
Inventors:
Christian Beil, Jochen Beninga, Joerg Birkenfeld, Gary J. Nabel, Huawei Qiu, Ercole Rao, Joerg Regula, Edward Seung, Ronnie Wei, Lan Wu, Zhen Xing, Ling Xu, Zhi-Yong Yang, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Type:
Grant
Filed:
August 22, 2023
Date of Patent:
February 18, 2025
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Sanjay Khandekar, Patrick Mayes, Joanna Opalinska
Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
Type:
Grant
Filed:
August 8, 2023
Date of Patent:
February 4, 2025
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers.
Type:
Grant
Filed:
May 30, 2018
Date of Patent:
February 4, 2025
Assignee:
STCUBE & CO., INC.
Inventors:
Stephen Sunghan Yoo, Yong-Sik Bong, Kyu Lee Han, Michael Joseph Surace
Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
Type:
Grant
Filed:
April 25, 2022
Date of Patent:
February 4, 2025
Assignee:
Zymeworks BC Inc.
Inventors:
Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Abstract: The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
January 14, 2025
Assignee:
The United States of America as Represented by the Department of Veterans Affairs
Inventors:
Richard H. Weisbart, Robert N. Nishimura
Abstract: The present invention relates to bioinformatics methods of in silico validation of circRNA junctions and selection of circRNA junctions for further validation, more particularly detecting sequence reads supporting circRNA junction in a highly computationally efficient manner.
Type:
Grant
Filed:
January 24, 2020
Date of Patent:
January 7, 2025
Assignee:
The Translational Genomics Research Institute
Inventors:
Shobana Sekar, Winnie Liang, Jonathan Keats
Abstract: The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38-binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38-expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.
Type:
Grant
Filed:
June 9, 2023
Date of Patent:
December 31, 2024
Assignees:
Molecular Templates, Inc., Millennium Pharmaceuticals, Inc.
Inventors:
Nibedita Chattopadhyay, Eric Poma, Erin Willert
Abstract: This disclosure relates to methods of and compositions for reducing expression or activity of a variant gene comprising at least one mutation as compared its wild-type gene, comprising introducing into a cell comprising the variant gene one or more DNA sequences encoding two or more gRNAs that are complementary to two or more target sequences in the variant gene, wherein at least one of the gRNAs hybridizes to a target sequence comprising a PAM site in the variant gene that results from a mutation to the variant gene creating the PAM site that does not exist in the wild-type gene or is operably linked to a mutated portion of the wild-type gene, at least one of the gRNAs hybridizes to a target sequence comprising a PAM site in an intron of the variant gene downstream or upstream from the PAM site, and a nucleic acid sequence encoding a CRISPR-associated endonuclease; wherein a CRISPR-associated endonuclease cleaves the variant gene at the target sequences; and expression or activity of the variant gene is redu
Type:
Grant
Filed:
February 4, 2022
Date of Patent:
December 24, 2024
Inventors:
Eric B. Kmiec, Byung-Chun Yoo, Pawel Bialk
Abstract: Disclosed herein, are nanoparticles comprising one or more immune-tolerant elastin-like polypeptide tetramers and one or more immune-tolerant elastin-like fusion molecules. Also, disclosed herein are pharmaceutical compositions including the nanoparticles; methods of administering the nanoparticles to patients for the treatment of cancer; and methods of making the nanoparticles.